中国实用外科杂志2012，Vol.32Issue(9)：716-719,4.
2012年NCCN指南结直肠癌新辅助及解救化疗方案变更与解读
Interpretations of the changes of colorectal cancer neo-adjurant and salvage chemotherapy regimen in 2012 version NCCN guideline
巴一1
作者信息
- 1. 天津医科大学附属肿瘤医院消化肿瘤内科,天津300060
- 折叠
摘要
Abstract
Some changes have been made on the colorectal cancer neo-adjuvant and the salvage chemotherapy regimens in the 2012 version of NCCN guideline. The combination of FOLFOX with cetuximab was removed from the salvage regimens and non-conversional neo-adjuvant chemotherapy regimens for KRAS wild type advanced colorectal cancer patients, because two phase Ⅲ randomized control trials presented with negative results. However, there are still rationales for the combination of oxaliplatin based regimens with EGFR antibody in the conversional neo-adjuvant chemotherapy. The combination of capecitabine with
bevacizumab is well tolerated, which is recommended as one of the initial treatment options for the patients who can' t tolerate intensive chemotherapy with advanced colorectal cancer. The concurrent chemoradiotherapy with capecitabine or infusional 5fluorouracil is recommended as the prior option for the patients with stage Ⅱ or Ⅲ rectal cancer. Capecitabine or infusional 5fluorouracil concurrent with radiotherapy is the prior neo-adjuvant regimen for the patients with rectal cancer, based on the results of three trials. Oxaliplatin can' t produce additional short term benefits.关键词
结直肠癌/新辅助/化疗/放疗Key words
colorectal cancer/neo-adjuvant/chemotherapy/radiotherapy分类
医药卫生引用本文复制引用
巴一..2012年NCCN指南结直肠癌新辅助及解救化疗方案变更与解读[J].中国实用外科杂志,2012,32(9):716-719,4.
